Katherine Glover-Collins

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Large-Core Needle Biopsy 90%
3. Occult Blood 88%
4. Triple Negative Breast Neoplasms 84%
5. Axilla 83%
6. Carcinoma, Intraductal, Noninfiltrating 82%
7. Cell Nucleus Active Transport 81%
8. Segmental Mastectomy 79%
9. Neoplasm Genes 75%
10. Hematologic Tests 72%
11. S Phase 68%
12. Early Detection of Cancer 66%
13. Colorectal Neoplasms 55%
14. African Americans 49%
15. Calcium 47%
16. Guidelines 44%
17. Sentinel Lymph Node Biopsy 43%
18. Survival 38%
19. Costs and Cost Analysis 36%
20. Community Health Workers 22%
21. Community Participation 21%
22. Rural Population 18%
23. Health 16%
24. Mastectomy 16%
25. Calcium-Calmodulin-Dependent Protein Kinase Type 2 16%
26. Health Care Reform 14%
27. Calcimycin 14%
28. Cost Savings 13%
29. Survival Rate 13%
30. Neoplasm Staging 12%
31. Research Ethics Committees 12%
32. Randomized Controlled Trials 11%
33. Institutional Practice 11%
34. DNA Damage 11%
35. Surgeons 10%
36. Cost-Benefit Analysis 10%
37. Cell Cycle 9%
38. Recurrence 9%
39. leptomycin B 9%
40. Control Groups 9%
41. Calcium Chelating Agents 9%
42. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 8%
43. Mortality 8%
44. Sensitivity and Specificity 8%
45. Calcium-Calmodulin-Dependent Protein Kinases 7%
46. Thapsigargin 7%
47. Calcium Ionophores 7%
48. Cell Line 7%
49. Delivery of Health Care 7%
50. Biopsy 7%